LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Kodu・Aktsiate loetelu・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Suletud

SektorTervishoid

17.12 -2.95

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.99

Max

17.64

Põhinäitajad
By Trading Economics
Sissetulek	-607K -51M
Müük	-28M 100M
Aktsiakasum	-0.46
Kasumimarginaal	-51.215
Töötajad	1,784
EBITDA	4.1M -44M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+83.15% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-308M 2.1B
Eelmine avamishind	20.07
Eelmine sulgemishind	17.12

Uudiste sentiment

By Acuity

34%

66%

79 / 344 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. juuni 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1. juuni 2026, 23:38 UTC

Omandamised, ülevõtmised, äriostud

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1. juuni 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1. juuni 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. juuni 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1. juuni 2026, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. juuni 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. juuni 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1. juuni 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Greg Abel's Week Is Off to Quite a Start -- WSJ

1. juuni 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1. juuni 2026, 21:22 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1. juuni 2026, 20:46 UTC

Omandamised, ülevõtmised, äriostud

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1. juuni 2026, 20:22 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Declares $11 Special Div

1. juuni 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1. juuni 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1. juuni 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1. juuni 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1. juuni 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1. juuni 2026, 18:54 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1. juuni 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1. juuni 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1. juuni 2026, 18:00 UTC

Omandamised, ülevõtmised, äriostud

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1. juuni 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1. juuni 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. juuni 2026, 17:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

83.15% tõus

12 kuu keskmine prognoos

Keskmine 32.4 USD 83.15%

Kõrge 44 USD

Madal 21.6 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Zai Lab Ltd ADR aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

79 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.